Anti-platelet therapy: Phosphodiesterase inhibitors

British Journal of Clinical Pharmacology

Volumn 72, Issue 4, 2011, Pages 634-646

  Gresele, Paolo ^a   Momi, Stefania ^a   Falcinelli, Emanuela ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Cilostazol; Dipyridamole; Phosphodiesterase inhibitor; Platelet

Indexed keywords

2 METHYL 5 NITROBENZENESULFONIC ACID DIMETHYLAMIDE; 9 (2 HYDROXY 3 NONYL)ADENINE; ACETYLSALICYLIC ACID; ANAGRELIDE; BAY 60 7550; BAY 73 6691; CILOSTAZOL; DIPYRIDAMOLE; DYPIRIDAMOLE; ETAZOLATE; IC 242; IC 86340; ILOPROST; LIXAZINONE; METHYLXANTHINE DERIVATIVE; MILRINONE; PENTOXIFYLLINE; PHOSPHODIESTERASE 2 INHIBITOR; PHOSPHODIESTERASE III INHIBITOR; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE V INHIBITOR; PIPERANOMETOZINE; ROLIPRAM; SILDENAFIL; TADALAFIL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VARDENAFIL; VINPOCETINE; ZAPRINAST; ZARDAVERINE;

HUMAN; HYDROLYSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION;

BLOOD PLATELETS; CLINICAL TRIALS AS TOPIC; DIPYRIDAMOLE; HUMANS; PHOSPHODIESTERASE INHIBITORS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; TETRAZOLES; THROMBOSIS;

EID: 80052617136     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2011.04034.x     Document Type: Review

References (119)

1. Daniel JL, Ashby B, Pulcinelli F. Platelet signaling: cAMP and cGMP. In: Platelets in Thrombotic and Non-Thrombotic Disorders, eds Gresele P, Page C, Fuster V, Vermylen J. Cambridge: Cambridge University Press, 2002; 290-304.
2. Bender AT, Beavo JA. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev 2006; 58: 488-520.
3. Grant PG, Colman RW. Purification and characterization of a human platelet cyclic nucleotide phosphodiesterase. Biochemistry 1984; 23: 1801-7.
4. Maurice DH, Haslam RJ. Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: inhibition of cyclic AMP breakdown by cyclic GMP. Mol Pharmacol 1990; 37: 671-81.
5. Hidaka H, Asano T. Human blood platelet 3':5'-cyclic nucleotide phosphodiesterase. Isolation of low-Km and high-Km phosphodiesterase. Biochim Biophys Acta 1976; 429: 485-97.
6. Haslam RJ, Dickinson NT, Jang EK. Cyclic nucleotides and phosphodiesterases in platelets. Thromb Haemost 1999; 82: 412-23.
7. Sutherland EW, Rall TW. Fractionation and characterization of a cyclic adenine ribonucleotide formed by tissue particles. J Biol Chem 1958; 232: 1077-91.
8. Butcher RW, Sutherland EW. Adenosine 3'-5'-phosphate in biological materials. Purification and properties of cyclic 3'-5'-nucleotide phosphodiesterase and use of this enzyme to characterize adenosine 3'-5'-phosphate in human urine. J Biol Chem 1962; 237: 1244-50.
9. Ardlie NG, Glew G, Schultz BG, Schwartz CJ. Inhibition and reversal of platelet aggregation by methylxanthines. Thromb Diath Haemorrh 1967; 18: 670-3.
10. Mills DCB, Smith JB. The influence on platelet aggregation of drugs that affect the accumulation of adenosine 3':5'-cyclic monophosphate in platelets. Biochem J 1971; 121: 185-96.
11. Evoniuk G, Jacobson KA, Shamim MT, Daly JW, Wurtman RJ. A1- and A2-selective adenosine antagonists: in vivo characterization of cardiovascular effects. J Pharmacol Exp Ther 1987; 242: 882-7.
12. Varani K, Portaluppi F, Merighi S, Ongini E, Belardinelli L, Borea PA. Caffeine alters A2A adenosine receptors and their function in human platelets. Circulation 1999; 99: 2499-502.
13. Jackson MR, Clagett GP. Antithrombotic therapy in peripheral arterial occlusive disease. Chest 2001; 119: 283S-99S.
14. Nenci GG, Gresele P, Agnelli G, Ballatori E. Effect of pentoxifylline on platelet aggregation. Pharmatherapeutica 1981; 2: 532-8.
15. Weithmann KU. The influence of pentoxifylline on interaction between blood vessel wall and platelets. IRCS Med Sci 1980; 8: 293-4.
16. Manrique RV, Manrique V. Platelet resistance to prostacyclin. Enhancement of the antiaggergatory effect of prostacyclin by pentoxifylline. Angiology 1987; 38: 101-8.
17. Dickinson NT, Jang EK, Haslam RJ. Activation of cGMP-stimulated phosphodiesterase by nitroprusside limits cAMP accumulation in human platelets: effects on platelet aggregation. Biochem J 1997; 323: 371-7.
18. Lima LM, Ormelli CB, Brito FF, Miranda AL, Fraga CA, Barreiro EJ. Synthesis and antiplatelet evaluation of novel aryl-sulfonamide derivatives, from natural safrole. Pharm Acta Helv 1999; 73: 281-92.
19. Brito FC, Kummerle AE, Lugnier C, Fraga CA, Barreiro EJ, Miranda AL. Novel thienylacylhydrazone derivatives inhibit platelet aggregation through cyclic nucleotides modulation and thromboxane A2 synthesis inhibition. Eur J Pharmacol 2010; 638: 1-3.
20. Silva CL, Noël F, Barreiro EJ. Cyclic GMP-dependent vasodilatory properties of LASSBio 294 in rat aorta. Br J Pharmacol 2002; 135: 293-8.
21. Diebold I, Djordjevic T, Petry A, Hatzelmann A, Tenor H, Hess J, Görlach A. Phosphodiesterase 2 mediates redox sensitive endothelial cell proliferation and angiogenesis by thrombin via Rac1 and NADPH oxidase 2. Circ Res 2009; 104: 1169-77.
22. Park H, Young Lee S, Lee DS, Yim M. Phosphodiesterase 4 inhibitor regulates the TRANCE/OPG ratio via COX-2 expression in a manner similar to PTH in osteoblasts. Biochem Biophys Res Commun 2007; 354: 178-83.
23. Sun B, Li H, Shakur Y, Hensley J, Hockman S, Kambayashi J, Manganiello VC, Liu Y. Role of phosphodiesterase type 3A and 3B in regulating platelet and cardiac function using subtype-selective knockout mice. Cell Signal 2007; 19: 1765-71.
24. a++ fluxes. J Pharmacol Exp Ther 1987; 243: 767-74.
25. Thiele J, Kvasnicka HM, Schmitt-Graeff A. Effects of anagrelide on megakaryopoiesis and platelet production. Semin Thromb Hemost 2006; 32: 352-61.
26. Silverstein MN, Petitt RM, Solberg LA, Fleming JS, Knight RC, Schacter LP. Anagrelide: a new drug for treating thrombocytosis. N Engl J Med 1988; 318: 1292-4.
27. Faxon DP, Creager MA, Smith SC, Pasternak RC, Olin JW, Bettmann MA, Criqui MH, Milani RV, Loscalzo J, Kaufman JA, Jones DW, Pearce WH. American Heart Association. Atherosclerotic vascular disease conference: executive summary: atherosclerotic vascular disease conference proceeding for healthcare professionals from a special writing group of the American Heart Association. Circulation 2004; 109: 2595-604.
28. Shrör K. The pharmacology of cilostazol. Diabetes Obes Metab 2002; 4: 14-9.
29. Kimura Y, Tani T, Kanbe T, Watanabe K. Effect of cilostazol on platelet aggregation and experimental thrombosis. Arzneimittelforschung 1985; 35: 1144-9.
30. Yasunaga K, Mase K. Antiaggregatory effect of oral cilostazol and recovery of platelet aggregability in patients with cerebrovascular disease. Arzneimittelforschung 1985; 35: 1189-92.
31. Kariyazono H, Nakamura K, Shinkawa T, Yamaguchi T, Sakata R, Yamada K. Inhibition of platelet aggregation and the release of P-selectin from platelets by cilostazol. Thromb Res 2001; 101: 445-53.
32. Igawa T, Tani T, Chijiwa T, Shiragiku T, Shimidzu S, Kawamura K, Kato S, Unemi F, Kimura Y. Potentiation of anti-platelet aggregating activity of cilostazol with vascular endothelial cells. Thromb Res 1990; 57: 617-23.
33. Minami N, Suzuki Y, Yamamoto M, Kihira H, Imai E, Wada H, Kimura Y, Ikeda Y, Shiku H, Nishikawa M. Inhibition of shear stress-induced platelet aggregation by cilostazol, a specific inhibitor of cGMP-inhibited phosphodiesterase, in vitro and ex vivo. Life Sci 1997; 61: PL383-9.
34. Tanigawa T, Nishikawa M, Kitai T, Ueda Y, Okinaka T, Makino K, Ito M, Isaka N, Ikeda Y, Shiku H, Nakano T. Increased platelet aggregability in response to shear stress in acute myocardial infarction and its inhibition by combined therapy with aspirin and cilostazol after coronary intervention. Am J Cardiol 2000; 85: 1054-9.
35. Jeong YH, Hwang JY, Kim IS, Park Y, Hwang SJ, Lee SW, Kwak CH, Park SW. Adding cilostazol to dual antiplatelet therapy achieves greater platelet inhibition than high maintenance dose clopidogrel in patients with acute myocardial infarction: results of the adjunctive cilostazol versus high maintenance dose clopidogrel in patients with AMI (ACCEL-AMI) study. Circ Cardiovasc Interv 2010; 3: 17-26.
36. Lee K, Kim JY, Yoo BS, Yoon J, Hong MK, Ahn MS, Choe H, Lee SH. Cilostazol augments the inhibition of platelet aggregation in clopidogrel low-responders. J Thromb Haemost 2010; 8: 2577-9.
37. Iwamoto T, Kin K, Miyazaki K, Shin K, Takasaki M. Recovery of platelet function after withdrawal of cilostazol administered orally for a long period. J Atheroscler Thromb 2003; 10: 348-54.
38. Nishio Y, Kashiwagi A, Takahara N, Hidaka H, Kikkawa R. Cilostazol, a cAMP phosphodiesterase inhibitor, attenuates the production of monocyte chemoattractant protein-1 in response to tumor necrosis factor-alpha in vascular endothelial cells. Horm Metab Res 1997; 29: 491-5.
39. Bramer SL, Forbes WP, Mallikaarjun S. Cilostazol pharmacokinetics after single and multiple oral doses in healthy males and patients with intermittent claudication resulting from peripheral arterial disease. Clin Pharmacokinet 1999; 37: (Suppl. 2): 1-11.
40. Suri A, Forbes WP, Bramer SL. Pharmacokinetics of multiple-dose oral cilostazol in middle-age and elderly men and women. J Clin Pharmacol 1998; 38: 144-50.
41. Akiyama H, Kudo S, Shimizu T. The metabolism of a new antithrombotic and vasodilating agent, cilostazol, in rat, dog and man. Arzneimittelforschung 1985; 35: 1133-40.
42. Yoo HD, Cho HY, Lee YB. Population pharmacokinetic analysis of cilostazol in healthy subjects with genetic polymorphisms of CYP3A5, CYP2C19 and ABCB1. Br J Clin Pharmacol 2010; 69: 27-37.
43. Tamai Y, Takami H, Nakahata R, Ono F, Munakata A. Comparison of the effects of acetylsalicylic acid, ticlopidine and cilostazol on primary hemostasis using a quantitative bleeding time test apparatus. Haemostasis 1999; 29: 269-76.
44. Wilhite DB, Comerota AJ, Schmieder FA, Throm RC, Gaughan JP, Rao AK. Managing PAD with multiple platelet inhibitors: the effect of combination therapy on bleeding time. J Vasc Surg 2003; 38: 710-3.
45. Ikeda Y, Kikuchi M, Murakami H, Satoh K, Murata M, Watanabe K, Ando Y. Comparison of the inhibitory effects of cilostazol, acetylsalicylic acid and ticlopidine on platelet functions ex vivo: randomized, double-blind cross-over study. Arzneimittelforschung 1987; 37: 563-6.
46. Comerota AJ. Effect on platelet function of cilostazol, clopidogrel, and aspirin, each alone or in combination. Atheroscler 2005; (Suppl.)6: 13-9.
47. Watanabe K, Nakase H, Kimura Y. Effect of cilostazol on experimental cerebral infarction in rabbits. Arzneimittelforschung 1986; 36: 1022-4.
48. Kohda N, Tani T, Nakayama S, Adachi T, Marukawa K, Ito R, Ishida K, Matsumoto Y, Kimura Y. Effect of cilostazol, a phosphodiesterase III inhibitor, on experimental thrombosis in the porcine carotid artery. Thromb Res 1999; 96: 261-8.
49. Kim CW, Yun JW, Bae IH, Park YH, Jeong YS, Park JW, Chung JH, Park YH, Lim KM. Evaluation of anti-platelet and anti-thrombotic effects of cilostazol with PFA-100(®) and Multiplate(®) whole blood aggregometer in vitro, ex vivo and FeCl(3)-induced thrombosis models in vivo. Thromb Res 2011; 127: 656-70.
50. Thompson PD, Zimet R, Forbes WP, Zhang P. Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication. Am J Cardiol 2002; 90: 1314-19.
51. Regensteiner JG, Ware JE Jr, McCarthy WJ, Zhang P, Forbes WP, Heckman J, Hiatt WR. Effect of cilostazol on treadmill walking, community-based walking ability, and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease: meta-analysis of six randomized controlled trials. J Am Geriatr Soc 2002; 50: 1939-46.
52. Gotoh F, Tohgi H, Hirai S, Terashi A, Fukuuchi Y, Otomo E, Shinohara Y, Itoh E, Matsuda T, Sawada T, Yamaguchi T, Nishimaru K, Ohashi Y. Cilostazol Stroke Prevention Study: a placebo-controlled double-blind trial for secondary prevention of cerebral infarction. J Stroke Cerebrovasc Dis 2000; 9: 147-57.
53. Shinohara Y, Katayama Y, Uchiyama S, Yamaguchi T, Handa S, Matsuoka K, Ohashi Y, Tanahashi N, Yamamoto H, Genka C, Kitagawa Y, Kusuoka H, Nishimaru K, Tsushima M, Koretsune Y, Sawada T, Hamada C. CSPS 2 group. Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurol 2010; 90: 959-68.
54. Uchiyama S, Demaerschalk BM, Goto S, Shinohara Y, Gotoh F, Stone WM, Money SR, Kwon SU. Stroke prevention by cilostazol in patients with atherothrombosis: meta-analysis of placebo-controlled randomized trials. J Stroke Cerebrovasc Dis 2009; 18: 482-90.
55. Han Y, Li Y, Wang S, Jing Q, Wang Z, Wang D, Shu Q, Tang X. Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: a randomized, controlled study. Am Heart J 2009; 157: 733-9.
56. Suh JW, Lee SP, Park KW, Lee HY, Kang HJ, Koo BK, Cho YS, Youn TJ, Chae IH, Choi DJ, Rha SW, Bae JH, Kwon TG, Bae JW, Cho MC, Kim HS. Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (Influence of CILostazol-based triple antiplatelet therapy ON ischemic complication after drug-eluting stenT implantation) trial. J Am Coll Cardiol 2011; 57: 280-9.
57. Weintraub WS, Foster J, Culler SD, Becker ER, Parker K, Zhang Z, Kolm P, Douglas JS Jr, Cilostazol for RESTenosis trial. Cilostazol for RESTenosis trial: methods for the economic and quality of life supplement to the cilostazol for RESTenosis (CREST) trial. J Invasive Cardiol 2004; 16: 257-9.
58. Ge J, Han H, Jiang H, Sun B, Chen J, Zhang S, Du Z. RACTS (Randomized Prospective Antiplatelet Trial of Cilostazol Versus Ticlopidine in Patients Undergoing Coronary Stenting) Trial Investigators RACTS: a prospective randomized antiplatelet trial of cilostazol versus ticlopidine in patients undergoing coronary stenting - long-term clinical and angiographic outcome. J Cardiovasc Pharmacol 2005; 46: 162-6.
59. Yamagami H, Sakai N, Matsumaru Y, Sakai C, Kai Y, Sugiu K, Fujinaka T, Matsumoto Y, Miyachi S, Yoshimura S, Hyogo T, Kuwayama N, Hyodo A. Periprocedural cilostazol treatment and restenosis after carotid artery stenting: the retrospective study of in-stent restenosis after carotid artery stenting (ReSISteR-CAS). J Stroke Cerebrovasc Dis 2010; [Epub ahead of print].
60. Jennings DL, Kalus JS. Addition of cilostazol to aspirin and a thienopyridine for prevention of restenosis after coronary artery stenting: a meta-analysis. Clin Pharmacol 2010; 50: 415-21.
61. Takigawa T, Matsumaru Y, Hayakawa M, Nemoto S, Matsumura A. Cilostazol reduces restenosis after carotid artery stenting. J Vasc Surg 2010; 51: 51-6.
62. Sorkin EM, Markham A. Cilostazol. Drugs Aging 1999; 14: 63-71.
63. Barradas MA, Jagroop A, O'Donoghue S, Jeremy JY, Mikhailidis DP. Effect of milrinone in human platelet shape change, aggregation and thromboxane A2 synthesis: an in vitro study. Thromb Res 1993; 71: 227-36.
64. Anfossi G, Massucco P, Piretto V, Mularoni E, Cavalot F, Mattiello L, Trovati M. Interplay between milrinone and adenosine in the inhibition of human platelet response. Gen Pharmacol 1996; 27: 1149-54.
65. Manns JM, Brenna KJ, Colman RW, Sheth SB. Differential regulation of human platelet responses by cGMP inhibited and stimulated cAMP phosphodiesterases. Thromb Haemost 2002; 87: 873-9.
66. Colucci WS. Cardiovascular effects of milrinone. Am Heart J 1991; 121: 1945-7.
67. Born GVR, Cross MJ. Inhibition of the aggregation of blood platelets by substances related to adenosine diphosphate. J Physiol 1963; 166: 29P-30P.
68. Elkeles RS, Hampton JR, Honour AJ, Mitchell JR Prichard JS. Effect of a pyrido-pyrimidine compound on platelet behaviour in vitro and in vivo. Lancet 1968; 2: 751-4.
69. Ahn HS, Crim W, Romano M, Sybertz E, Pitts B. Effects of selective inhibitors on cyclic nucleotide phosphodieterase of rabbit aorta. Biochem Pharmacol 1989; 38: 3331-9.
70. Schwartz L, Bourassa G, Lesperance J, Eastwood C, Kazim F. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. N Engl J Med 1988; 318: 1714-9.
71. Klabunde RE. Dipyridamole inhibition of adenosine metabolism in human blood. Eur J Pharmacol 1993; 93: 21-6.
72. Gresele P, Zoja C, Deckmyn H, Arnout J, Vermylen J, Verstraete M. Dipyridamole inhibits platelet aggregation in whole blood. Thromb Haemost 1983; 30: 852-6.
73. Gresele P, Arnout J, Deckmyn H, Vermylen J. Mechanism of the antiplatelet action of dipyridamole in whole blood: modulation of adenosine concentration and activity. Thromb Haemost 1986; 55: 12-8.
74. De La Cruz JP, Garcia PJ, Sanchez F, Cuesta F. Dipyridamole inhibits platelet aggregation induced by oxygen-derived free radicals. Thromb Res 1992; 66: 277-85.
75. Perez Requeio JL, Santos MT, Valles J, Aznar J. Antiplatelet activity of dipirydamole in non anticoagulated whole blood. Thromb Res 1988; 52: 279-86.
76. Muller TH, Su CA, Weisemberg H, Brickl R, Nehmiz G, Eisert WG. Dipyridamole alone or combined with low-dose acetylsalicylic acid inhibits platelet aggregation in human whole blood ex vivo. Br J Clin Pharmacol 1990; 30: 179-86.
77. Saniabadi AR, Fisher TC, McLaren M, Belch JF, Forbes CD. Effects of dipyridamole alone or in combination with aspirin on whole blood platelet aggregation, PGI2 generation, and red cell deformability ex vivo in man. Cardiovasc Res 1991; 25: 177-83.
78. Soderback U, Sollevi A, Wallen NH, Larsson PT, Hjemdhal P. Anti-aggregatory effects of physiological concentrations of adenosine in human whole blood as assessed by filtragometry. Clin Sci 1991; 81: 691-4.
79. Harker LA, Kadatz RA. Mechanism of action of dipyridamole. Thromb Res 1983; (Suppl.)4: 39 - 46.
80. Sakuma I, Akaishi Y, Fukao M, Makita Y, Makita MA, Kobayashi T, Matsuno K, Miyazaki T, Yasuda H. Dipyridamole potentiates the anti-aggregating effect of endothelium-derived relaxing factor. Thromb Res 1990; 60: 87-90.
81. Aktas B, Utz A, Hoenig-Liedl P, Walter U, Geiger J. Dipyridamole enhances NO/cGMP-mediated vasodilator-stimulated phosphoprotein phosphorylation and signaling in human platelets: in vitro and in vivo/ex vivo studies. Stroke 2003; 34: 764-9.
82. Utz A, Aktas B, Honig-Liedl P, Walter U, Geriger J. Dipyridamole effects at physiolgical plasma concentrations on platelets in vitro and in vivo. Naunyn Schmiedebergs Arch Pharmacol 2001; 363: 3.
83. Iuliano L, Colavita AR, Camastra P, Bello V, Quintarelli C, Alessandroni M, Piovella F, Violi F. Protection of low density lipoprotein oxidation at chemical and cellular level by the antioxidant drug dipyridamole. Br J Pharmacol 1996; 119: 1438-43.
84. Pascual C, Romay C. Effect of antioxidant and chemiluminescence produced by reactive oxygen species. J Biolumin Chemilumin 1992; 7: 123-32.
85. Gresele P, Arnout J, Vermylen J. Dipyridamole inhibits leukotriene B4 synthesis. Thromb Haemost 1987; 57: 235.
86. Deckmyn H, Gresele P, Arnout J, Todisco A, Vermylen J. Prolonging prostacyclin production by nafazatrom or dipyridamole. Lancet 1984; 2: 410-1.
87. Deckmyn H, Zoja D, Arnout J, Todisco A, Vanden Bulcke F, D'Hondt L, Hendrickx N, Gresele P, Vermylen J. Partial isolation and function of the prostacyclin regulating plasma factor. Clin Sci 1985; 69: 383-93.
88. Chakrabarti S, Freedman JE. Dipyridamole, cerebrovascular disease, and the vasculature. Vasc Pharmacol 2008; 48: 143-9.
89. Kim HH, Liao JK. Translational therapeutics of dipyridamole. Arterioscler Thromb Vasc Biol 2008; 28: s39-42.
90. Eisert WG. Near-field amplification of antithrombotic effects of dipyridamole through vessel wall cells. Neurology 2001; 57: S20-3.
91. Iimura O, Kusano E, Amemiya M, Muto S, Ikeda U, Shimada K, Asano Y. Dipyridamole enhances interleukin 1 beta stimulated nitric oxide production by cultured rat vascular smooth muscle cells. Eur J Pharmacol 1996; 296: 319-26.
92. Weyrich AS, Denis MM, Kuhlmann-Eyre JR, Spencer ED, Dixon DA, Marathe GK, McIntyre TM, Zimmerman GA, Prescott SM. Dipyridamole selectively inhibits inflammatory gene expression in platelet-monocyte aggregates. Circulation 2005; 111: 633-42.
93. Mattiello T, Guerriero R, Lotti LV, Trifirò E, Felli MP, Barbarulo A, Pucci B, Gazzaniga P, Gaudio C, Frati L, Pulcinelli FM. Aspirin extrusion from human platelets though multidrug resistance protein-4 mediated transport: evidence of a reduced drug action in patients after coronary artery bypass grafting. J Am Coll Cardiol 2011; in press.
94. Gresele P, Arnout J, Deckmyn H, Vermylen J. Combining antiplatelet agents: potentiation between aspirin and dipyridamole. Lancet 1985; 1: 937-8.
95. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996; 143: 1-13.
96. Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A, ESPRIT Study Group. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 2006; 367: 1665-73.
97. Weber E, Haas TA, Muller TH, Eisert WG, Hirsh J, Richardson M, Buchanan MR. Relationship between vessel wall 13-HODE synthesis and vessel wall thrombogenicity following injury: influence of salicylate and dipyridamole treatment. Thromb Res 1990; 57: 383-92.
98. Van Ryn JM, Lorenz M, Merk H, Buchanan MR, Eisert WG. Accumulation of radiolabelled platelets and fibrin on the carotid artery of rabbits after angioplasty: effects of heparin and dipyridamole. Thromb Haemost 2003; 90: 1179-86.
99. Venkatesh PK, Pattillo CB, Branch B, Hood J, Thoma S, Illum S, Pardue S, Teng X, Patel RP, Kevil CG. Dipyridamole enhances ischaemia-induced arteriogenesis through an endocrine nitrite/nitric oxide-dependent pathway. Cardiovasc Res 2010; 85: 661-70.
100. Verro P, Gorelick PB, Nguyen D. Aspirin plus dipyridamole versus aspirin for prevention of vascular events after stroke or TIA: a meta-analysis. Stroke 2008; 39: 1358-63.
101. Adams RJ, Albers G, Alberts MJ, Benavente O, Furie K, Goldstein LB, Gorelick P, Halperin J, Harbaugh R, Johnston SC, Katzan I, Kelly-Hayes M, Kenton EJ, Marks M, Sacco RL, Schwamm LH. American Heart Association; American Stroke Association. Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke 2008; 39: 1647-52.
102. Sacco RL, Diener HC, Yusuf S, Cotton D, Ounpuu S, Lawton WA, Palesch Y, Martin RH, Albers GW, Bath P, Bornstein N, Chan BP, Chen ST, Cunha L, Dahlöf B, De Keyser J, Donnan GA, Estol C, Gorelick P, Gu V, Hermansson K, Hilbrich L, Kaste M, Lu C, Machnig T, Pais P, Roberts R, Skvortsova V, Teal P, Toni D, Vandermaelen C, Voigt T, Weber M, Yoon BW, PRoFESS Study Group. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med 2008; 359: 1238-51.
103. Diener HC, Sacco RL, Yusuf S, Cotton D, Ounpuu S, Lawton WA, Palesch Y, Martin RH, Albers GW, Bath P, Bornstein N, Chan BP, Chen ST, Cunha L, Dahlöf B, De Keyser J, Donnan GA, Estol C, Gorelick P, Gu V, Hermansson K, Hilbrich L, Kaste M, Lu C, Machnig T, Pais P, Roberts R, Skvortsova V, Teal P, Toni D, VanderMaelen C, Voigt T, Weber M, Yoon BW, Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) study group. Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study. Lancet Neurol 2008; 7: 875-84.
104. Stein PD, Alpert JS, Bussey HI, Dalen JE, Turpie AG. Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. Chest 2001; 119: 220S-7S.
105. De Schryver EL, Algra A, van Gijn J. Dipyridamole for preventing stroke and other vascular events in patients with vascular disease. Cochrane Database Syst Rev 2006; (2): CD001820. 1-43.
106. Murray KJ. Phosphodiesterase Va inhibitors. Drug News Perspect 1993; 6: 150-6.
107. Rudd RM, Gellert AR, Studdy PR, Geddes DM. Inhibition of exercise induced asthma by an orally absorbed mast cell stabilizer (M&B22948). Br J Dis Chest 1983; 77: 78-86.
108. Dunkern TR, Hatzelmann A. The effect of Sildenafil on human platelet secretory function is controlled by a complex interplay between phosphodiesterases 2, 3 and 5. Cell Signal 2005; 17: 331-9.
109. Schwartz BG, Kloner RA. Drug interactions with phosphodiesterase-5 inhibitors used for the treatment of erectile dysfunction or pulmonary hypertension. Circulation 2010; 122: 88-95.
110. Wallis RM, Corbin JD, Francis SH, Ellis P. Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. Am J Cardiol 1999; 83: 3C-12C.
111. Cheitlin MD, Hutter AM Jr, Brindis RG, Ganz P, Kaul S, Russell RO Jr, Zusman RM. Use of sildenafil (Viagra) in patients with cardiovascular disease. Technology and practice executive committee. Circulation 1999; 99: 168-77.
112. Berkels R, Klotz T, Sticht G, Englemann U, Klaus W. Modulation of human platelet aggregation by the phosphodiesterase type 5 inhibitor sildenafil. J Cardiovasc Pharmacol 2001; 37: 413-21.
113. Halcox JP, Nour KR, Zalos G, Mincemoyer RA, Waclawiw M, Rivera CE, Willie G, Ellahham S, Quyyumi AA. The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia. J Am Coll Cardiol 2002; 40: 1232-40.
114. Galie N, Rubin LJ, Simonneau G. Phosphodiesterase inhibitors for pulmonary hypertension. N Engl J Med 2010; 362: 559-60.
115. Young JM. Expert opinion: vardenafil. Expert Opin Investig Drugs 2002; 1: 1487-96.
116. Corbin JD, Francis SH. Pharmacology of phosphodiesterase-5 inhibitors. Int J Clin Pract 2002; 56: 453-9.
117. De Bon E, Bonanni G, Saggiorato G, Bassi P, Cella G. Effects of tadalafil on platelets and endothelium in patients with erectile dysfunction and cardiovascular risk factors: a pilot study. Angiology 2010; 61: 602-6.
118. Gresele P, Falcinelli E, Momi S. Potentiation and priming of platelet activation: a potential target for antiplatelet therapy. Trends Pharmacol Sci 2008; 29: 352-60.
119. Curtin R, FitzGerald DJ. A cold start for oral glycoprotein IIb/IIIa antagonists. Eur Heart J 2000; 21: 1992-4.